Sign up Australia
Proactive Investors - Run By Investors For Investors

Benitec endorsement of Pain Program from US and European clinical pain specialists

Benitec endorsement of Pain Program from US and European clinical pain specialists

Benitec's (ASX: BLT) company strategy is focused on developing new therapies for life-threatening diseases based on long-term silencing of genes.

In an update to the market, Benitec has highlighted that the company has received a strong endorsement of the Pain Program from U.S. and European clinical pain specialists.

Benitec is currently attempting to fast track the pre-clinical, clinical and commercial development of the company's lead program, which is a novel gene silencing therapeutic for intractable cancer-associated neuropathic pain.

In addition, Benitec has appointed U.S. based Ground Zero Pharmaceuticals as the CRO to advance the pain program into clinical testing under a USFDA-approved protocol.

Peter French, chief executive officer for Benitec, commented "These findings validate our pain program directly from the pain clinicians themselves.

"It reinforces our focus on the pain program, and provide the impetus for Benitec to mobilize additional resources to the program and to progress to the next stage of Benitec's commercial outreach for this program in the U.S. and Europe with Campbell Alliance."

 



Register here to be notified of future BLT Company articles
View full BLT profile

Benitec Ltd. Timeline

Newswire
August 18 2015
Newswire
November 11 2014

Related Articles

AZN2.jpg
November 16 2016
Silence is a platform technology company operating in a key area for the future of medicine - Canaccord Genuity.
1-SG02055.jpg
March 23 2016
e-Therapeutics is now targeting partners to accelerate the development of its drug discovery engine and commercialise compounds.
Concept of a DNA strand
September 13 2016
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making incredible advances altering the inner workings of the human body to tackle deadly diseases.

© Proactive Investors 2016

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.